{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["138"],"submitter":["Wehrhahn MC"],"pubmed_abstract":["A total of 1080 individual patient samples (158 positive serology samples from confirmed, predominantly mildly symptomatic COVID-19 patients and 922 serology negative including 496 collected pre-COVID) from four states in Australia were analysed on four commercial SARS-CoV-2 serological assays targeting antibodies to different antigens (Roche Elecsys and Abbott Architect: nucleocapsid; Diasorin Liaison and Euroimmun: spike). A subset was compared to immunofluorescent antibody (IFA) and micro-neutralisation. Sensitivity and specificity of the Roche (n = 1033), Abbott (n = 806), Diasorin (n = 1034) and Euroimmun (n = 175) were 93.7 %/99.5 %, 90.2 %/99.4 %, 88.6 %/98.6 % and 91.3 %/98.8 %, respectively. ROC analysis with specificity held at 99 % increased the sensitivity for the Roche and Abb"],"journal":["Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology"],"pagination":["104797"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7968170"],"repository":["biostudies-literature"],"pubmed_title":["An evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian population."],"pmcid":["PMC7968170"],"pubmed_authors":["Wehrhahn MC","Waring L","Robson J","Yu M","O'Sullivan MVN","Evans J","Marland E","Newcombe JP","Powell H","Roy J","Figtree M","Hueston L","Hainke L","Brown SJ","Chong S","Khan S"],"additional_accession":[]},"is_claimable":false,"name":"An evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian population.","description":"A total of 1080 individual patient samples (158 positive serology samples from confirmed, predominantly mildly symptomatic COVID-19 patients and 922 serology negative including 496 collected pre-COVID) from four states in Australia were analysed on four commercial SARS-CoV-2 serological assays targeting antibodies to different antigens (Roche Elecsys and Abbott Architect: nucleocapsid; Diasorin Liaison and Euroimmun: spike). A subset was compared to immunofluorescent antibody (IFA) and micro-neutralisation. Sensitivity and specificity of the Roche (n = 1033), Abbott (n = 806), Diasorin (n = 1034) and Euroimmun (n = 175) were 93.7 %/99.5 %, 90.2 %/99.4 %, 88.6 %/98.6 % and 91.3 %/98.8 %, respectively. ROC analysis with specificity held at 99 % increased the sensitivity for the Roche and Abb","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-18T16:39:27.267Z","creation":"2022-02-09T15:05:18.142Z"},"accession":"S-EPMC7968170","cross_references":{"pubmed":["33770657"],"doi":["10.1016/j.jcv.2021.104797"]}}